Danaher Corporation (LON:0R2B)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 100.83B |
| Revenue (ttm) | 19.07B |
| Net Income (ttm) | 3.11B |
| Shares Out | n/a |
| EPS (ttm) | 4.23 |
| PE Ratio | 32.38 |
| Forward PE | n/a |
| Dividend | 0.88 (0.46%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 74 |
| Average Volume | 3,958 |
| Open | 189.25 |
| Previous Close | 191.01 |
| Day's Range | 186.71 - 189.25 |
| 52-Week Range | 182.16 - 269.23 |
| Beta | 0.90 |
| RSI | 41.79 |
| Earnings Date | Apr 22, 2025 |
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment offers bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manuf... [Read more]
Financial Performance
In 2024, Danaher's revenue was $23.88 billion, a decrease of -0.06% compared to the previous year's $23.89 billion. Earnings were $3.90 billion, a decrease of -17.79%.
Financial numbers in USD Financial StatementsNews
Lightning Round: Robinhood has more downside from here, says Jim Cramer
'Mad Money' host Jim Cramer weighs in on stocks including: Archer Aviation, GlobalFoundries, Dow, Old Republic International, Danaher, Robinhood, and more.
3 Wide-Moat Dividend Stars For A Championship Portfolio
I linked investing to baseball, showing how consistency, like the A's Moneyball approach, wins long term. Steady dividend growers and low-volatility stocks outperform, especially in rocky markets. Top...
Becton Dickinson in talks with rivals over divesting life sciences unit
Medical devices maker to discuss options for $21bn division with Thermo Fisher, Danaher and other smaller rivals
Danaher: Operational Excellence Meets Cyclical Pause - A Hold Amid Recovery Prospects
Discover how Danaher refocuses on life sciences with strong fundamentals and strategic growth, despite near-term challenges.
Danaher Corporation: A Mixed Bag Of Strength And Stagnation
Danaher: Some Near-Term Headwinds, But Good Long-Term Prospects And Low Valuations
Danaher has good medium to long-term revenue and margin growth prospects, and the valuation is lower than historical levels. Read why DHR stock is a Buy.
Looking Into Danaher's Recent Short Interest
Danaher's (NYSE: DHR) short percent of float has risen 31.63% since its last report. The company recently reported that it has 8.17 million shares sold short , which is 1.29% of all regular shares th...
8 Upcoming Dividend Increases, Including A King
Highlighting eight companies with upcoming dividend increases, four exceeding 10%, and an average increase of 11.4%, median at 9%. My investment strategy focuses on buying, holding, and expanding stak...
Danaher: Near 5-Year Low Is A Great Entry Point
Check Out What Whales Are Doing With DHR
Investors with significant funds have taken a bearish position in Danaher (NYSE: DHR), a development that retail traders should be aware of. This was brought to our attention today through our monito...
Goldman upgrades this conglomerate, sees 20% upside
Danaher shares are finally trading at a more attractive valuation, according to Goldman Sachs.
Danaher Schedules First Quarter 2025 Earnings Conference Call
WASHINGTON , March 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2025 on Tuesday, April 22, 2025 ...
Danaher Stock Has Fallen Far Enough. Buy It Now, Says Analyst.
Unpacking the Latest Options Trading Trends in Danaher
Whales with a lot of money to spend have taken a noticeably bearish stance on Danaher . Looking at options history for Danaher (NYSE: DHR) we detected 10 trades. If we consider the specifics of each ...
Danaher upgraded to Buy at Stifel on top-line growth opportunities
Unlocking Intrinsic Value: Analysis of Danaher Corp
Unlocking Intrinsic Value: Analysis of Danaher Corp
Beckman Coulter Announces FDA clearance of DxC 500i Clinical Analyzer, an integrated Clinical Chemistry and Immunoassay System
The new DxC 500i Analyzer Offers Flexibility and Scalability with Broad Chemistry and Immunoassay Assay Menu BREA, Calif. , March 10, 2025 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagn...
Danaher Corporation (DHR) TD Cowen 45th Annual Health Care Conference Transcript
Danaher Corporation (NYSE:DHR) TD Cowen 45th Annual Health Care Conference Call March 5, 2025 10:30 AM ETCompany ParticipantsRainer Blair – President and...
Danaher to Present at TD Cowen Health Care Conference
WASHINGTON , Feb. 25, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the TD Cowen Healthcare Conferen...
Industrial Laser Marking Machine Market To Reach USD 6.41 Billion by 2032, Growing at CAGR 8.1% | Coherent, Inc., Danaher Corporation, Epilog Laser
An industrial laser marking machine uses laser technology to engrave, etch, or mark materials with precision for identification, branding, or tracking. An industrial laser marking machine uses laser t...
Decoding Danaher Corp (DHR): A Strategic SWOT Insight
Decoding Danaher Corp (DHR): A Strategic SWOT Insight
Danaher Corporation (DHR) Announces Director Appointment and Stock Plan Amendment
Danaher Corporation (DHR) Announces Director Appointment and Stock Plan Amendment
Danaher raises dividend by 18.5%
Danaher Announces Appointment of Charles Lamanna to Danaher Board
WASHINGTON , Feb. 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that it has appointed Charles Lamanna to its Board of Directors and to the Board's Science & Technology Commi...
Danaher Increases Quarterly Dividend
WASHINGTON , Feb. 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common s...